SG10202105186XA - Methods for treating multiple osteochondroma (mo) - Google Patents

Methods for treating multiple osteochondroma (mo)

Info

Publication number
SG10202105186XA
SG10202105186XA SG10202105186XA SG10202105186XA SG10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA SG 10202105186X A SG10202105186X A SG 10202105186XA
Authority
SG
Singapore
Prior art keywords
methods
treating multiple
multiple osteochondroma
osteochondroma
treating
Prior art date
Application number
SG10202105186XA
Inventor
Isabelle Lemire
Michael Harvey
Donna Roy Grogan
Clarissa Desjardins
Original Assignee
Clementia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clementia Pharmaceuticals Inc filed Critical Clementia Pharmaceuticals Inc
Publication of SG10202105186XA publication Critical patent/SG10202105186XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10202105186XA 2016-11-16 2017-11-16 Methods for treating multiple osteochondroma (mo) SG10202105186XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662423019P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
SG10202105186XA true SG10202105186XA (en) 2021-06-29

Family

ID=62144988

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202105186XA SG10202105186XA (en) 2016-11-16 2017-11-16 Methods for treating multiple osteochondroma (mo)

Country Status (14)

Country Link
US (1) US10980778B2 (en)
EP (1) EP3541380B1 (en)
JP (1) JP7018957B2 (en)
KR (1) KR20190100187A (en)
CN (1) CN110381939B (en)
AU (1) AU2017359673B2 (en)
BR (1) BR112019009929A2 (en)
CA (1) CA3043807A1 (en)
EA (1) EA039050B1 (en)
ES (1) ES2907696T3 (en)
IL (1) IL266605A (en)
MX (1) MX2019005700A (en)
SG (1) SG10202105186XA (en)
WO (1) WO2018090137A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186505A4 (en) * 2020-06-11 2024-06-19 Yang Sheng Tang Company, Ltd. Use of palovarotene in treatment against hbv virus
CN118460478A (en) * 2024-07-15 2024-08-09 山东大学 Multi-osteochondroma induced pluripotent stem cell line and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
JP2003526677A (en) 2000-03-14 2003-09-09 ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ Compositions and methods for affecting bone formation
MXPA03002861A (en) 2000-10-02 2003-07-14 Hoffmann La Roche Retinoids for the treatment of emphysema.
AU2002329276B2 (en) 2001-09-18 2008-04-24 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists I
ES2325063T3 (en) 2001-09-18 2009-08-25 F. Hoffmann-La Roche Ag RETINOID AGONISTS II OF REPLACED UREA.
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (en) 2004-01-23 2005-08-04 Yasuyoshi Uchida Muscle-regenerating agent
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
EA200701998A1 (en) 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. COMPOSITIONS FOR INJECTION OF NANOPARTICLES IMMUNE DEPRESSIVE COMPOUNDS
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
WO2007037188A1 (en) 2005-09-27 2007-04-05 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by increase in vasopermeability
JP2009531375A (en) * 2006-03-31 2009-09-03 エフ.ホフマン−ラ ロシュ アーゲー Method for producing retinoid compound
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
EP2083862A4 (en) 2006-10-27 2012-09-19 Lpath Inc Compositions and methods for treating ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US8969350B2 (en) 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
WO2010088735A1 (en) 2009-02-05 2010-08-12 Regenertech Pty Ltd Method of producing progenitor cells from differentiated cells
WO2011011513A1 (en) 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
MX361414B (en) 2010-09-01 2018-12-05 Univ Jefferson Composition and method for muscle repair and regeneration.
US20120077786A1 (en) 2010-09-27 2012-03-29 Byron David A Methods and compositions for disease treatment using inhalation
CN103702967A (en) * 2011-03-14 2014-04-02 貝丝以色列女执事医疗中心 Methods and compositions for treatment of proliferative disorders
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2726084A1 (en) 2011-07-01 2014-05-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating pathologic heterotopic ossification
NZ708756A (en) 2012-11-08 2019-07-26 Univ Yamaguchi Therapeutic agent for keratoconjunctive disorders
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital Bmp inhibitors and methods of use thereof
JP6542192B2 (en) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. BMP inhibitors and methods of use thereof
PT3000466T (en) 2013-05-22 2018-11-27 Univ Yamaguchi Inhibitor for retinochoroidal disorders
JP2017536411A (en) 2014-10-01 2017-12-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. BMP inhibiting composition and BMP inhibiting method
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
EP4249490A3 (en) * 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
JP7018957B2 (en) 2022-02-14
ES2907696T3 (en) 2022-04-26
KR20190100187A (en) 2019-08-28
US10980778B2 (en) 2021-04-20
CN110381939B (en) 2022-12-02
EP3541380B1 (en) 2021-12-15
WO2018090137A1 (en) 2018-05-24
EP3541380A4 (en) 2020-12-09
US20190275005A1 (en) 2019-09-12
BR112019009929A2 (en) 2019-08-20
EA039050B1 (en) 2021-11-26
CA3043807A1 (en) 2018-05-24
IL266605A (en) 2019-07-31
MX2019005700A (en) 2020-01-21
CN110381939A (en) 2019-10-25
JP2019534336A (en) 2019-11-28
EA201991208A1 (en) 2019-10-31
EP3541380A1 (en) 2019-09-25
AU2017359673B2 (en) 2021-10-21
AU2017359673A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
EP3500289A4 (en) Methods for treating tracheobronchomalacia
PL2997550T5 (en) Method for controlling access
IL279308A (en) Methods for treating hepcidin-mediated disorders
EP3171878A4 (en) Methods for treating paramyxoviruses
HK1244217A1 (en) Methods for treating proteinopathies
EP3542829A4 (en) Apparatus for treating clothing
EP3193865A4 (en) Methods for treating brain metastasis
HK1248133A1 (en) Methods for treating neuroblastoma
HK1255871A1 (en) Cerdulatinib for treating myeloma
HK1250649A1 (en) Anti-s100a8 for treating leukemia
HK1255481A1 (en) Methods for treating hcv
ZA201708386B (en) Treatment for multiple myeloma (mm)
EP3507838C0 (en) Device for treating parts
EP3244914A4 (en) Methods for treating tauopathy
IL266605A (en) Methods for treating multiple osteochondroma (mo)
EP3148307B8 (en) Method for treating seeds
EP3131904A4 (en) Methods for treating hypersomnia
EP3130586A4 (en) Process for treating homoserine-based compound
HK1257072A1 (en) Method for treating multiple sclerosis
IL249616A0 (en) Methods for treating infections
EP3313398A4 (en) Methods for treating hcv
EP3246432A4 (en) Method for treating parts
HK1256371A1 (en) Methods for treating tumours
AU2015904922A0 (en) Methods for treating pelvic triphosis
AU2015903130A0 (en) Methods for treating tumours